Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 02/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 495 publications
Breath-activated nanomedicine: Ambrisentan-loaded chitosomes for pulmonary arterial hypertension.
Journal: International journal of pharmaceutics
Published: October 06, 2025
Breath-activated nanomedicine: Ambrisentan-loaded chitosomes for pulmonary arterial hypertension.
Journal: International journal of pharmaceutics
Published: October 06, 2025
Targeting Endothelin A and Angiotensin type 1 receptors with Ambrisentan and Losartan ameliorates cisplatin-induced injury in human tubuloids.
Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: October 03, 2025
Ambrisentan ameliorates methotrexate-induced pulmonary injury in rats: involvement of ET-1/ETA, NF-κB, and MMP-9/TIMP-1 pathways.
Journal: Toxicology and applied pharmacology
Published: September 20, 2025
Pathogenic Glomulin Gene Variant in a Patient with Idiopathic Pulmonary Arterial Hypertension: A Novel Association Case Report.
Journal: Reports (MDPI)
Published: September 16, 2025
Tadalafil for Treatment of Pulmonary Hypertension: Mechanisms, Evidence, and Emerging Perspectives.
Journal: Cardiology in review
Published: September 11, 2025
In brief: Embryotoxicity REMS removal for endothelin receptor antagonists.
Journal: The Medical letter on drugs and therapeutics
Published: September 09, 2025
Initial Body Weight as an Important Factor for Improving the Reliability and Translational Relevance of the Preclinical Monocrotaline-Induced Rat Pulmonary Hypertension Model.
Journal: International journal of molecular sciences
Published: August 14, 2025
Statement of retraction: clinical adverse events to letairis: a real-world drug safety study based on FDA Adverse Event Reporting System (FAERS).
Journal: Expert opinion on drug safety
Published: August 08, 2025
Selection of Endothelin Receptor Antagonists in the Treatment of Pulmonary Arterial Hypertension: A Comprehensive Narrative Review.
Journal: Advances in therapy
Published: August 06, 2025
Phosphodiesterase type 5 inhibitor plus endothelin receptor antagonist compared to either alone for group 1 pulmonary arterial hypertension.
Journal: The Cochrane database of systematic reviews
Published: August 04, 2025
Patient Perceptions of and Experiences with Risk Evaluation and Mitigation Strategies.
Journal: Clinical pharmacology and therapeutics
Published: July 07, 2025
Last Updated: 02/24/2026